Sharecare aims to drive behavior change with VR acquisition

With the acquisition of VR developer BioLucid, Sharecare hopes to use empathy to encourage behavior change.

Drugmakers set their sights on the next potential blockbuster disease: NASH

Drugmakers set their sights on the next potential blockbuster disease: NASH

A race has emerged in a new disease space estimated to be worth billions of dollars.

BBDO picks up Neulasta; FCB gains Galderma and Sandoz work in the U.S.

BBDO picks up Neulasta; FCB gains Galderma and Sandoz work in the U.S.

Agency networks such as BBDO, Saatchi & Saatchi, and FCB reported key pharma account wins in August, according to R3.

How to get more women in the C-suite, according to IPG, Unilever, and AOL

How to get more women in the C-suite, according to IPG, Unilever, and AOL

A new report analyzing gender parity in advertising found that men tend to endorse other men at higher rates than women. Execs share their insights about the issue.

Five things for pharma marketers to know: Friday, September 30, 2016

Five things for pharma marketers to know: Friday, September 30, 2016

Vertex drug challenged by low refill rates; the FDA has issued only 4 warning or untitled letters this year; Horizon settles PBM-rebate suit

Five things for pharma marketers to know: Thursday, September 29, 2016

Five things for pharma marketers to know: Thursday, September 29, 2016

Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump

Five things for pharma marketers to know: Wednesday, September 28, 2016

Five things for pharma marketers to know: Wednesday, September 28, 2016

Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry

Which drugmakers have the healthiest presence on social media?

Which drugmakers have the healthiest presence on social media?

A study of the social media activity of pharmaceutical firms finds that Lilly is the most active, but Novo Nordisk and Boehringer Ingelheim have better engagement.

Five things for pharma marketers to know: Tuesday, September 27, 2016

Five things for pharma marketers to know: Tuesday, September 27, 2016

Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest

Uber partners with startup to take patients to the doctor

Uber partners with startup to take patients to the doctor

A 2005 study estimated that 3.6 million people do not receive nonemergency medical care because they don't have access to transportation.

The FDA denies approval of abuse-deterrent opioid after promotional warning

The FDA denies approval of abuse-deterrent opioid after promotional warning

The agency denied Pain Therapeutics' and Durect's abuse-deterrent opioid in a complete response letter after warning the drugmakers about how they promoted the drug.

Five things for pharma marketers to know: Monday, September 26, 2016

Five things for pharma marketers to know: Monday, September 26, 2016

Pfizer drops plans to split into two companies; Merck's Keytruda gains competitive edge in China; Apple may be developing health software

The FDA, Astellas, and Accenture use innovation competitions to help address business challenges

The FDA, Astellas, and Accenture use innovation competitions to help address business challenges

The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.

The FDA approves Amgen's biosimilar version of Humira

The FDA approves Amgen's biosimilar version of Humira

Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.

Agency Spotlight


OPINION

Email Newsletters